Skip to content

Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation

Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation in Healthy Population

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01100671
Enrollment
120
Registered
2010-04-09
Start date
2010-04-30
Completion date
2011-08-31
Last updated
2018-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

atherosclerosis, vascular inflammation, MDCT, 18FDG-PET

Brief summary

Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.cardiac multidetector-row CT can provide measurements of coronary artery calcium (CAC), the degree of stenosis, and the characteristics of plaque including its potential vulnerability. Therefore, the purpose of the investigators study is to compare the usefulness of 18 FDG-PET and MDCT in assessing the vascular inflammatory status and vulnerability.

Interventions

This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting

Sponsors

Korea University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy patients for visiting routine medical check in our clinic

Exclusion criteria

* History of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization) * Diabetes * Stage 2 hypertension (resting blood pressure, ≥ 160/100 mmHg) * Malignancy * Severe renal or hepatic disease * Subjects taking medications that might affect inflammation such as NSIAD and statin

Design outcomes

Primary

MeasureTime frame
Correlation between vascular inflammatory status measured by 18FDG PET and MDCT20weeks

Secondary

MeasureTime frame
Comparison the correlation with inflammatory marker and vascular inflammatory status assessed by 18FDG PET and MDCT20 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026